Clinical Trial

Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy

Recruiting Phase 1

Record status

This record was last updated August 14, 2024 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.

Summary

Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-07-22.

Trial Details

NCT Number	NCT06522581
Lead Sponsor	Armed Forces Hospital, Pakistan
Conditions	Hypoxic Ischemic Encephalopathy of Newborn
Enrollment	200 participants
Start Date	2024-01-01
Primary Completion	2025-01-01 (estimated)
Study Completion	2025-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-14